1125345 - Macrogenics Inc - SEC Form 4 Insider Trading Screener

Manufactured Goods - Chemicals - Pharmaceutical Preparations - MGNX (1125345)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
42 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P1+8-3+16+74
S9-0+1-4-22

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

D
2017-11-21
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOM - OptEx$4.70+5,00030,000+20%+$23,500
D
2017-11-21
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOS - Sale+OE$20.00-5,00030,000-14%-$100,000
D
2017-10-25
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOM - OptEx$4.70+10,00030,000+50%+$47,000
D
2017-10-25
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOS - Sale+OE$20.00-10,00030,000-25%-$200,000
D
2017-09-05
MGNXKarrels JamesSVP, CFO, SecretaryM - OptEx$0.94+5,000110,331+5%+$4,700
D
2017-09-05
MGNXRisser Eric BlasiusSVP, Chief Business OfficerM - OptEx$0.94+2,0006,000+50%+$1,880
D
2017-07-26
MGNXBonvini EzioSVP, Research, CSOM - OptEx$1.23+53,264146,658+57%+$65,248
D
2017-06-05
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOM - OptEx$4.70+5,00030,000+20%+$23,500
D
2017-06-05
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOS - Sale+OE$20.00-5,00030,000-14%-$100,000
2017-04-28
MGNXSaran AtulSVP, GCF - Tax$21.61-1,86216,986-10%-$40,238-3-15
D
2017-04-19
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOM - OptEx$4.70+15,00030,000+100%+$70,500-1+4
D
2017-04-19
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOS - Sale+OE$20.00-15,00030,000-33%-$300,000-1+4
D
2017-01-25
MGNXKarrels JamesSVP, CFO, SecretaryM - OptEx$0.94+5,000105,331+5%+$4,700+1+1+7
D
2017-01-17
MGNXKoenig ScottPres, CEOM - OptEx$0.94+79,8981,004,358+9%+$75,104+1-4+9
DM
2016-02-11
MGNXBonvini EzioSVP, Research, CSOM - OptEx$0.94+17,311100,944+21%+$16,272-1-7+10-18
AD
2016-10-03
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOM - OptEx$4.70+10,0000-100%+$47,000+4+2+18-14
AD
2016-10-03
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOS - Sale+OE$29.34-10,0000-100%-$293,400+4+2+18-14
D
2016-10-03
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOM - OptEx$4.70+10,0000-100%+$47,000-1-2-28-43
D
2016-10-03
MGNXWigginton Jon MarcSVP, Clinical Dev., CMOS - Sale+OE$29.34-10,0000-100%-$293,400-1-2-28-43
D
2016-10-03
MGNXCilinski LynnVP, Controller, TreasurerM - OptEx$0.94+6,2311,923-145%+$5,857-1-2-28-43
D
2016-10-03
MGNXCilinski LynnVP, Controller, TreasurerS - Sale+OE$29.28-6,2311,923-76%-$182,444-1-2-28-43
D
2016-08-01
MGNXWigginton Jon MarcSVP Clinical Dev, CMOM - OptEx$4.70+20,0000-100%+$94,000+2-1-6-44
D
2016-08-01
MGNXWigginton Jon MarcSVP Clinical Dev, CMOS - Sale+OE$30.78-20,0000-100%-$615,600+2-1-6-44
D
2016-07-01
MGNXWigginton Jon MarcSVP Clinical Dev, CMOM - OptEx$4.70+5,0000-100%+$23,500-1+5+21-24
D
2016-07-01
MGNXWigginton Jon MarcSVP Clinical Dev, CMOS - Sale+OE$27.22-5,0000-100%-$136,100-1+5+21-24
D
2016-07-01
MGNXCilinski LynnVP, Controller, TreasurerM - OptEx$0.94+8,9221,923-127%+$8,387-1+5+21-24
D
2016-07-01
MGNXCilinski LynnVP, Controller, TreasurerS - Sale+OE$27.22-8,9221,923-82%-$242,857-1+5+21-24
A
2016-04-28
MGNXSaran AtulSVP, GCF - Tax$20.84-1,86218,848-9%-$38,804+1+9+5+7
D
2016-05-27
MGNXCilinski LynnVP, Controller, TreasurerM - OptEx$0.94+5,0001,923-162%+$4,700+2+10-4+17
D
2016-05-27
MGNXCilinski LynnVP, Controller, TreasurerS - Sale+OE$25.00-5,0001,923-72%-$125,000+2+10-4+17
D
2016-05-16
MGNXKoenig ScottPres, CEOM - OptEx$0.94+34,619924,460+4%+$32,542-1+24+40+63
D
2016-05-11
MGNXKoenig ScottPres, CEOM - OptEx$0.94+79,898889,841+10%+$75,104+3+27+57+61
2016-04-28
MGNXSaran AtulSVP, GCF - Tax$20.84-1,73018,980-8%-$36,053-1-10+18+18
2016-03-03
MGNXCosta Paulo FDirP - Purchase$17.20+10,00059,435+20%+$172,000+8-3+16+74
2016-02-25
MGNXWigginton Jon MarcSVP, Clinical Dev, CMOA - Grant$0.00+30,00030,000New+$0+1+18+8+85
D
2016-02-08
MGNXRisser Eric BlasiusSVP, Business DevelopmentM - OptEx$0.94+2,5004,000+167%+$2,350-5+9+3+94
D
2016-01-29
MGNXKarrels JamesSVP, CFO, SecretaryM - OptEx$0.94+10,000100,331+11%+$9,400-6-17-13+54
D
2016-01-07
MGNXStein Kathryn ESVP, Product Dev., RegulatoryM - OptEx$0.86+52,35095,555+121%+$44,825-7-10-35+9
D
2016-01-07
MGNXBonvini EzioSVP, ResearchM - OptEx$0.94+13,31683,633+19%+$12,517-7-10-35+9
D
2016-01-04
MGNXWigginton Jon MarcSVP, ClinicalM - OptEx$4.70+10,0000-100%+$47,000-6-10-30-5
D
2016-01-04
MGNXWigginton Jon MarcSVP, ClinicalS - Sale+OE$29.64-10,0000-100%-$296,400-6-10-30-5
D
2015-12-23
MGNXRisser Eric BlasiusSVP, Business DevelopmentM - OptEx$0.94+1,5001,500New+$1,410+1+1-28-14

Real-time CSV? Options? Alerts? Contact us!
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top